SITC Cancer Immunotherapy CONNECT

SITC 2020, 9-14

Deadline extended: SITC 2020 abstract submissions due Aug. 25!

Submit a regular abstract, Young Investigator Award abstract, late-breaking abstract application or Immunotherapy Resistance and Failure Pre-Conference Program presentation application for SITC 2020. All authors of accepted abstracts will have the opportunity to virtually present their research and have it published as a supplement in the Journal for ImmunoTherapy of Cancer (JITC).

SITC Cancer Immunotherapy Guidelines – Free Multiple Myeloma Webinar
Learn about SITC’s clinical practice guidelines for immunotherapy for multiple myeloma in this free SITC webinar on Sept. 3, 2020, at 7 p.m. EDT.


Earn a Certificate in Cancer Immunotherapy

The Certificate in Cancer Immunotherapy consists of eight independent learning modules—all approved for CME, CNE, CPE and MOC credits—that can be stacked to earn the SITC Graduate in Cancer Immunotherapy (SITC-G) designation. The SITC-G designation identifies a healthcare provider as completing specialized training in cancer immunotherapy.  

SITC 2020 9-14

SITC 2020 reimagined as a fully virtual experience

SITC's 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) will be reimagined as a fully VIRTUAL experience this year, and in celebration of the society's 35th anniversary, all SITC members are invited to register for FREE!


JITC Increases Impact Factor to 9.913
The Journal for ImmunoTherapy of Cancer (JITC), recently received new metrics on citations tabulated in Web of Science and Scopus.


JITC Now Providing Continuing Medical Education (CME) Credit to Reviewers


SITC COVID-19 Resources

The Society for Immunotherapy of Cancer (SITC) is committed to providing the most current COVID-19 information and resources to its members and the oncology community at large.



Why I'm a SITC Member

Join Mary Disis, MD, FACP, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.

Become a SITC Member

New Online Patient Course Available: Understanding Cancer Immunotherapy 
Access SITC’s dedicated resource for patients and caregivers to learn about cancer immunotherapy


Immunotherapy for the Treatment of Lung Cancer 

A free, interactive course, part of the Advances in Cancer Immunotherapy™ online education series.

Register Now

Consistent with the Safer at Home Order issued by the Department of Health Services of the State of Wisconsin, all SITC Executive Office staff will be working remotely beginning March 25 and are best reached through email. General inquiries can be sent to Thank you for understanding.


Explore resources and educational opportunities for cancer patients and those who advocate for them.







Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.







Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.






Latest Discussions

  • Purpose: Conversations directly relevant to patient care Audience: Practicing clinicians and staff, clinical investigators Suggested topics: demographics, clinical presentation, diagnostic testing, patient management issues/insights, patterns in ...

    3 people recommend this.
  • Purpose: Conversations directly relevant to research Audience: Laboratory and translational scientists Suggested topics: Data sharing, emerging literature, sample/tissue collection, model/reagent development, opportunities for collaboration, translational ...

    1 person recommends this.
  • This comprehensive review outlines some of the immunotherapies that are currently being used to treat COVID-19 patients. Included are details of convalescent plasma therapy, monoclonal antibodies, cytokine therapy, mesenchymal stem cell therapy, intravenous ...

Follow the SITC Twitter Feed.


Connect with colleagues at these Upcoming Events.


Ignite the SITC Sparkathon

Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.


Learn More


The Journal & The Blog

Journal for ImmunoTherapy of Cancer

An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.

Learn More


Making Cure a Reality

It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.


Learn More